See the DrugPatentWatch profile for azacitidine

Azacitidine is a drug that has been shown to have an impact on histone modifications associated with graft-versus-host disease (GVHD) [1]. GVHD is a common complication that can occur after a stem cell transplant, where the transplanted cells attack the recipient's body [2].

Histone modifications are changes that occur in the structure of histone proteins, which are responsible for packaging DNA in the nucleus of a cell [3]. These modifications can affect gene expression and have been linked to various diseases, including GVHD [4].

According to a study published in the journal Blood, azacitidine can modulate histone modifications associated with GVHD [1]. The study found that azacitidine treatment led to a decrease in the levels of H3K9me2, a histone modification that has been linked to GVHD [1]. Additionally, the study found that azacitidine treatment led to an increase in the levels of H3K4me3, a histone modification that is associated with active gene expression [1].

These findings suggest that azacitidine may be a useful drug for treating GVHD by modulating histone modifications [1]. However, more research is needed to fully understand the effects of azacitidine on histone modifications and GVHD.

In summary, azacitidine has been shown to have an impact on histone modifications associated with GVHD, specifically by decreasing the levels of H3K9me2 and increasing the levels of H3K4me3 [1]. These findings suggest that azacitidine may be a useful drug for treating GVHD, but more research is needed to confirm its effectiveness.

Sources:

1. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887735/>
2. <https://www.ncbi.nlm.nih.gov/books/NBK221766/>
3. <https://www.ncbi.nlm.nih.gov/books/NBK21595/>
4. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164222/>
5. <https://www.drugpatentwatch.com/drugs/azacitidine>